Originally developed for the treatment of B-cell lymphomas, RTX has gained broad application in autoimmune demyelinating diseases such as MS, NMOSD, and myelin oligodendrocyte glycoprotein-associated disease. Here, MOG is linked to myeloid sarcoma.